Literature DB >> 3643802

LAV/HTLV-III antibody status and immunological abnormalities in haemophiliac patients.

J J Huart, M Maniez, A Parquet-Gernez, M Goudemand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3643802     DOI： 10.1007/BF00321042

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


× No keyword cloud information.
  5 in total

1.  High prevalence of lymphadenopathy virus (LAV) in European haemophiliacs.

Authors:  M Melbye; R J Biggar; J C Chermann; L Montagnier; S Stenbjerg; P Ebbesen
Journal:  Lancet       Date:  1984-07-07       Impact factor: 79.321

2.  Antibody to lymphadenopathy-associated virus in haemophiliacs with and without AIDS.

Authors:  R B Ramsey; E L Palmer; J S McDougal; V S Kalyanaraman; D W Jackson; T L Chorba; R C Holman; B L Evatt
Journal:  Lancet       Date:  1984-08-18       Impact factor: 79.321

3.  T-lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates.

Authors:  J E Menitove; R H Aster; J T Casper; S J Lauer; J L Gottschall; J E Williams; J C Gill; D V Wheeler; V Piaskowski; P Kirchner; R R Montgomery
Journal:  N Engl J Med       Date:  1983-01-13       Impact factor: 91.245

4.  [Immunological study of a population of hemophiliacs treated with non-commercial fractions].

Authors:  J J Huart; P Boulanger; A Parquet; M Goudemand
Journal:  Rev Fr Transfus Immunohematol       Date:  1984-09

5.  Immunoglobulin G antibodies to lymphadenopathy-associated virus in differently treated French and Belgian hemophiliacs.

Authors:  C Rouzioux; F Brun-Vezinet; A M Couroucé; C Gazengel; D Vergoz; J Desmyter; J Vermylen; C Vermylen; D Klatzmann; D Geroldi
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.